RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

Core Insights - Johnson & Johnson announced promising overall survival data from the Phase 3 MARIPOSA study, indicating that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) may significantly improve survival rates compared to osimertinib for patients with EGFR-mutated non-small cell lung cancer (NSCLC) [1][6][9] - The company aims to redefine treatment expectations for patients with EGFR mutations, emphasizing the potential for longer survival and improved quality of life with the new treatment regimen [2][3] Company Developments - The Phase 3 MARIPOSA study results will be presented at the 2025 European Lung Cancer Congress, showcasing the efficacy of RYBREVANT® plus LAZCLUZE™ in first-line treatment for advanced NSCLC [1][6] - Additional studies, including the Phase 2 COCOON study, will present data on a dermatologic regimen aimed at enhancing patient experience during treatment [2][6] Industry Context - NSCLC accounts for 80 to 85 percent of all lung cancer cases, with EGFR mutations being a significant driver of the disease [13] - The five-year survival rate for advanced NSCLC patients with EGFR mutations treated with current therapies remains low, highlighting the need for innovative treatment options like RYBREVANT® and LAZCLUZE™ [13][30]